Comparison of liposomal cisplatin versus cisplatin in non-squamous cell non-small-cell lung cancer

PURPOSE: Liposomal cisplatin was developed to reduce the systemic toxicity of cisplatin, particularly the nephrotoxicity, and it has been used in combination with other agents in pancreatic and head and neck cancers and non-small-cell lung cancer (NSCLC). Our objective was to compare the effectivene...

Descripción completa

Detalles Bibliográficos
Autores principales: Stathopoulos, G. P., Antoniou, D., Dimitroulis, J., Stathopoulos, J., Marosis, K., Michalopoulou, P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2011
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3180559/
https://www.ncbi.nlm.nih.gov/pubmed/21301848
http://dx.doi.org/10.1007/s00280-011-1572-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3180559/
https://www.ncbi.nlm.nih.gov/pubmed/21301848
http://dx.doi.org/10.1007/s00280-011-1572-5

Ejemplares similares